A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Paclitaxel; Sunitinib

Criteria

Inclusion Criteria:

• Diagnosis of advanced breast cancer.

• Measurable disease as per RECIST (Response Evaluation Criterion) in Solid Tumors or bone-only disease.

• ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.

Exclusion Criteria:

• No prior treatment with cytotoxics in the advanced disease setting.

• HER2/neu positive disease unless trastuzumab was previously received or is contraindicated.

• Treatment with a taxane in the adjuvant setting unless disease free interval >12 months after end of treatment.